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Abstract 
Background This study had two aims: to investigate the capacity of individuals with 
intellectual disabilities to make decisions about their medications, and to evaluate 
whether the provision of training (information) sessions on medications would 
increase their capacity. 
Method 28 adults (18 male and 10 female), with a mild to moderate intellectual 
disability were included in this study and they were taking either Epilim, Metformin 
or Haloperidol medications. The participants were split into groups that comprised of 
participants taking the same medications. Each of the groups received three training 
sessions on their own medications. Capacity to consent was measured by the A-ACQ, 
which was specially adapted for each medication type from the original measure 
(ACQ). Receptive language ability was measured by the BPVS-II. 
Results  A two factor mixed ANOVA analysis indicated that the provision of 
training had improved the capacity of the participants to give informed consent to 
taking their medications. Analysis using Pearson’s correlations indicated that 
increased levels of receptive language ability correlated with greater increases in the 
ability to give informed consent to taking medication. 
Conclusions The provision of information that is formatted in a way that individuals 
with intellectual disabilities can understand may be a useful way to increase 
knowledge on medications. Further research that investigates the provision of 
information with larger samples is warranted.  
Keywords: training, adults, intellectual disability, capacity, consent, medication   
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Introduction 
In the past people with intellectual disabilities often had their decisions made 
for them (Murphy & Clare, 2003), despite the fact that in most developed countries 
there was a general respect for autonomy, and most non-disabled adults were assumed 
to be competent and were deemed to have the right to accept or refuse treatment, even 
if their decision appeared to be irrational (Nicholls, 1993; Grisso and Appelbaum, 
1998).  More recently, people with intellectual disabilities have been asserting their 
right to make their own decisions and, in England and Wales, this right is enshrined in 
law for those with capacity, under the Mental Capacity Act 2005 (Department for 
Constitutional Affairs, 2007). 
 
Capacity and informed consent 
Determining capacity to give informed consent to treatment is complex, and 
needs to consider an individual’s rights to make their own decisions as well as the 
need to  protect them from any potential harm (Wong, Clare, Gunn & Holland, 1999). 
Historically, three approaches have been utilised to assess an individual’s capacity to 
consent: the diagnostic, outcome, and functional approaches (Murphy & Clare, 2003). 
The functional approach is the most frequently used approach to establish capacity, 
and is now enshrined in law in England and Wales in the MCA 2005. This approach 
establishes whether an individual’s skills, abilities and knowledge are sufficient to 
enable them to make a decision in a particular situation (Grisso, 1986). A functional 
framework approach is decision-specific and allows for fluctuations in capacity and 
for the possibility of increasing capacity to consent (Murphy & Clare, 2003). 
 
Evaluation of informed consent 
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Evaluating capacity to give informed consent, in England and Wales, requires 
the assessment of whether a person can understand and retain information pertinent to 
the decision; whether he or she can utilise and manipulate that information and 
whether he or she can communicate a decision (Department of Constitutional Affairs, 
2007). Individuals with intellectual disabilities may have difficulties in the 
comprehension of information regarding treatment (Arscott, 1997). The more severe 
the person’s intellectual disability, the more impaired that individual is likely to be in 
understanding information (Morris, Niederbuhl & Mahr, 1993; Arscott, Dagnan & 
Stenfert Kroese, 1999; Cea and Fisher, 2003). Adults with intellectual disabilities may 
also struggle with understanding and appreciating risks and benefits of treatment and 
alternatives available, weighing the alternatives up, and understanding their right to 
say no (Cea and Fisher, 2003). Their thinking processes may be concrete and they 
may have poor problem-solving abilities, as well as often having little experience of 
choice-making (Curran & Hollins, 1994).  
 
Medication and learning disabilities 
Adults with intellectual disabilities are more likely to experience mental 
illness than non-disabled adults and they are prone to develop chronic health 
problems, epilepsy, and physical and sensory disabilities (DOH, 2001). They are often 
prescribed a range of medications both for these conditions and to reduce challenging 
behaviours, for example, aggression. The majority of research on this population 
regarding medication has focused on the use of psychotropic medications (Arscott, 
Stenfert Kroese & Dagnan, 2000; Crossley & Withers, 2009) and there appears to be a 
high occurrence of the prescribing of these medications (Robertson, Emerson, 
Gregory, Hatton et al, 2000; Stenfert Kroese, Dewhurst & Holmes, 2001) despite 
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scant investigation of the occurrence and frequency of side-effects of medication in 
the population with intellectual disabilities.  
 
Knowledge of medication 
Individuals with intellectual disabilities, like anyone else, should be given 
information about the function of their medication, reasons for prescription, side-
effects, risks and benefits and alternatives to taking the medication. Limited research 
exists on the knowledge this population possesses about their medication. One study 
that investigated the amount of knowledge that individuals with intellectual 
disabilities have about their medication found that most participants knew the 
administration time of their medication, consequences for not taking it, reasons for 
taking it and the function of medication but, they appeared to lack knowledge on the 
side-effects and alternatives to medication (Arscott et al., 2000). However, the 
number of participants used was small (n=30) and caution needs to be taken in the 
generalisation of the results. However, Crossley & Withers (2009) in a small 
qualitative study (n=8) reported similar findings. 
Strydom, Forster, Wilkie, Edwards & Hall (2001) reviewed information 
leaflets that are supplied with medications and designed some specifically for 
individuals with intellectual disabilities (Strydom et al., 2001). However, their 
randomised trial of the effects of these leaflets on knowledge about medication 
suggested that the leaflets did not improve knowledge (Strydom & Hall, 2001). 
Heslop et al. (2005) and Fretwell & Felce (2007) have found that carers also seemed 
to lack knowledge about reasons why the disabled person in their care was prescribed 
medication and they lacked knowledge about its side-effects. Most of the carers in the 
Heslop et al. study expressed satisfaction with the knowledge they possessed, though 
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some wanted to know more about the function of the tablets, duration of treatment 
and potential risks (Heslop et al., 2005). Few of the carers in Fretwell & Felce (2007) 
however were satisfied with the information they had and most felt they required 
training. Larger scale postal surveys of staff opinions and knowledge of medication 
have produced similar calls for further training for staff in intellectual disability 
services (Christian, Snycerski, Singh & Poling 1999). 
 
Aims of this research  
The present study had two aims:  to investigate the capacity of people with 
intellectual disabilities to make decisions about their medication and to evaluate 
whether the provision of training (information) sessions on medication to people with 
intellectual disabilities would increase their capacity.  
Method 
This study was given ethical approval from the relevant NHS ethical body at 
the time (Central Office for Research Ethics Committees - COREC). The manager of 
the local Social Services (SS) department dealing with intellectual disability services 
also gave approval for the research to take place.  
Participants 
 The inclusion criteria were: adults with a mild to moderate intellectual 
disability, who were aged 18 years or over, males or females, currently taking either 
Metformin (diabetic), Haloperidol (psychotropic) or Epilim (anti-convulsant) 
medications. Participants were excluded if they could not consent to participate in the 
study, if they were not taking medication or were on multiple medications. It should 
be noted that participants were only included if they had capacity to give their consent 
to participate in the study.  
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After consultation with community nurses and day centre staff (see 
Procedure), in a Social Services run intellectual disability service, 39 potential 
participants were identified, who met the above criteria for ID, age and medication. 
However, four withdrew their consent, and a further seven were not suitable for 
inclusion because their level of intellectual disability was too severe and / or their 
communication difficulties were too extreme for them to be able to consent to the 
research. Therefore, 28 adults, with mild to moderate intellectual disabilities were 
recruited. 
Measures 
 British Picture Vocabulary Scale (BPVS-II - Dunn et al., 1997). 
The BPVS-II, consisting of 168 items, is a standardised measure of language 
comprehension. A list of words is read to the individual and, for each word, they have 
to choose from four possible pictures and point to the picture that they believe best 
depicts the word given (all pictures are line drawings). A receptive vocabulary age 
equivalent score is then obtained. Good reliability has been reported (median 
Cronbach’s alpha 0.93, median split-half 0.86). The BPVS-II is assumed to have 
validity as it is derived from the original version; however, this has not been 
independently established. Nevertheless, it correlates closely with IQ scores (Dunn et 
al., 1997; Glenn & Cunningham, 2005).  
 Adapted – Assessment of Capacity Questionnaire (A-ACQ - Adapted from 
Morris et al., 1993; Arscott et al., 1999).  
The original measure (Morris et al., 1993) incorporated three hypothetical 
vignettes, presented in the second person (“you”), that described individuals being 
offered behavioural, surgical and medical interventions. Questions were asked which 
aimed to assess an individual’s understanding of the presenting problem, the 
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procedure, risks, benefits and alternatives. A scoring schedule was employed that 
measured the minimum levels of knowledge and voluntariness that was needed to 
determine whether an individual was able to give informed consent. The original 
ACQ appeared to be a reliable measure with highly significant inter-rater reliability 
(kappa coefficient 0.79) (Morris et al., 1993). The measure was slightly adapted by 
Arscott et al., 1999, and it also appeared to have face and content validity (Arscott et 
al., 1999).  
 The adapted ACQ (A-ACQ) utilised in this study, was altered from Arscott et 
al’s version so that it incorporated vignettes on three different medications 
(Haloperidol, Metformin and Epilim) in order to ensure that the vignette matched the 
participant’s circumstances (each participant was only presented with one vignette, 
the one that matched their medication). 16 (57.1%) participants were taking Epilim, 
five (17.9%) participants were taking Haloperidol and seven (25%) had been 
prescribed Metformin medications.  
The vignettes were presented in the first person, to make the information 
relevant to the participant. Pictures accompanied the scenarios and were presented 
alongside the information. Questions followed the information to assess an 
individual’s knowledge and understanding of the problem, knowledge and 
understanding of the treatment (medication), risks, benefits, rights, choices and 
alternatives (for details of the questions, see Table 1). Scores for each question ranged 
between zero and two, depending on the degree to which the answer showed a good 
comprehension of the material. The maximum possible score was 14. For a participant 
to be judged as having capacity to consent to their medication, they had to gain a 
score of at least one point on each of the questions on the A-ACQ. Test re-test 
                      Training to Give Informed Consent to Medication    
 9 
reliability was excellent (see Results section). (Copies of the A-ACQ may be obtained 
from the first author). 
Table 1 about here 
________________ 
Procedure 
The chief investigator (CI) visited day care provisions and residential homes 
for adults with intellectual disabilities, in conjunction with a community nurse who 
normally visited potential participants, to initially introduce the project. A member of 
the day service staff or a carer (in residential homes) was also present at these 
meetings with the CI. Specifically adapted information sheets giving both written and 
pictorial information about the study were given to participants at these visits. Each 
individual was given one week to decide if they wanted to participate and staff were 
asked to help them understand and consider the information sheet. Individuals who 
expressed an interest in being included in the study, attended a group with other 
potential participants at a convenient time for them. The project was explained again 
in depth and written consent  was obtained by the CI and a community nurse The CI 
ensured that every participant fully understood the nature of the research, the risks and 
benefits of participating and that they could withdraw their consent at any time. The 
carer and General Practitioner (GP) of each of the participants who gave their consent, 
were also sent letters and information sheets about the study. None of the participants 
was under the care of a Psychiatrist.  
At the first meeting with each participant, following consent, The British 
Picture Vocabulary Scale-II (BPVS-II) (Dunn, Dunn, Whetton & Burley, 1997) was 
administered to assess the participant’s language comprehension. Background and 
demographic information were also recorded (gender, age, residential setting, length 
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of time on medication). The participant’s ability to give informed consent to their own 
medication was then assessed using the adapted version of the ACQ.  
After a period of two weeks (a ‘control’ period), the participants completed 
the A-ACQ for a second time before intervention, in order to investigate whether the 
experience of the first assessment and having time to consider information from 
baseline assessment would produce any significant changes at re-assessment. The 
participants were then split into groups that comprised participants taking the same 
medication. Each of the groups then received three training sessions on their own 
medications: this was provided in a group-training format (by the first author). 
Participants were told that they could invite their carers to attend as well, if they 
wished, but none did. 
The content of the training included: function of medication, possible side-
effects, risks, benefits and alternatives to medication; employing pictorial aids as 
necessary. In session one, the reasons for the prescribing of each medication, the 
physiological effects and any possible side-effects were discussed. Session two 
included a review of all the positive and negative things that could occur if the 
individual continued to take their medications. Session three incorporated a discussion 
on the alternatives available to the person instead of taking their medication, for 
example, avoiding alcohol or flashing lights for those taking anti-epileptics. The 
Mental Capacity Act was reviewed and capacity to consent was explained. An 
emphasis was placed on the correct information about medication being given to the 
individual and the rights of the individual to ask other relevant professionals (GP) for 
further information or clarification. It was stressed that each person who is deemed to 
be capacitous had the right to take or refuse their prescribed medications. There was 
no take-home information. 
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Capacity to consent was then measured again, two weeks after training, using 
the A-ACQ.  
 
Data analysis 
 Data were explored (using the Statistical Package for the Social Science 
(SPSS) Version 14.0) to examine skew, kurtosis and normality. BPVS-II skew was 
0.93 and kurtosis –1.23; A-ACQ (baseline) skew was –1.24 and kurtosis –1.04; A-
ACQ (first re-assessment) skew was –1.33 and kurtosis –0.81; A-ACQ (second re-
assessment) skew was –1.17 and kurtosis –0.46. The data were thus normally 
distributed and parametric statistics were used.  
 Pearson’s correlations were carried out to investigate the associations between 
all of the following: the BPVS-II scores, A-ACQ (baseline) assessment scores, the A-
ACQ scores at first and second re-assessment, and the change in A-ACQ scores from 
first to second re-assessment. 
A two factor mixed factorial analysis of variance (ANOVA) was used with the 
A-ACQ scores to investigate significant interaction effects between the groups and 
occasions. The type of medication (groups) was the between subject factor and the A-
ACQ scores (occasions) was the within subject factor.  
The significance level used throughout was p<0.01 in view of the number of 
analyses conducted, in order to avoid type 1 errors.  
Results 
Demographic information  
The age range of the 28 participants was between 20 to 56 years (mean = 
38.71 years, SD = 10.41 years) and there were 18 males and ten females. The majority 
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of participants (13) resided in supported living, while 6 lived in residential homes, 6 
lived with their own family, one was living alone and one in a family placement. 
 
Medication 
16 (57.1%) participants were taking Epilim, five (17.9%) participants were 
taking Haloperidol and seven (25%) had been prescribed Metformin medications. The 
participants had been taking their medications for an average duration of 8.46 years 
(range = 1-30 years). On average, participants were taking Epilim for 12.63 years 
(range = 1-30 years), Haloperidol for 2.4 years (range = 1 to 4 years) and Metformin 
for 3.29 years (range = 1-5 years).   
 The mean BPVS-II raw score for the participants was 70.46 (SD = 5.51, range 
of scores = 63 to 81). The mean vocabulary age equivalent score was 6 yrs  8 mths ( 
range 6yrs 2 mths to 7yrs 11mths).  
 The range of scores on the A-ACQ at baseline assessment was one to seven 
(mean score = 4.61, SD = 2.06). The range of scores at first re-assessment before 
treatment (control) was one to seven (mean score = 4.68, SD = 1.96). The mean score 
on this measure at second re-assessment (post-intervention) was 6.61 (SD = 2.23), 
with a range of scores between two and ten.  
 
Receptive language comprehension ability and informed consent 
 It was hypothesised that individuals with intellectual disabilities who had a 
higher level of receptive language comprehension, as measured by the BPVS-II, 
would have gained higher scores on the A-ACQ. A series of parametric correlations 
(Pearson’s correlations) were performed to test for significant associations between 
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the BPVS-II scores and the pre-training (baseline assessment), first re-assessment and 
second re-assessment (post-intervention) A-ACQ scores.  
 Highly significant positive correlations (all two-tailed, all n=28) were found 
between the BPVS-II scores and scores on the A-ACQ baseline assessment (r = 0.903, 
p<0.01), A-ACQ first re-assessment (r = 0.873, p<0.01), and A-ACQ second re-
assessment (r = 0.915, p<0.01). The correlation between the BPVS-II score and the 
change in A-ACQ scores (from first re-assessment to second re-assessment, i.e. after 
training) was not quite significant (p=0.033). 
 
Association of scores on A-ACQ 
 A correlation was performed on the scores on the A-ACQ baseline assessment 
(pre-treatment) and the scores at first (control) and second re-assessment (post-
treatment). Highly significant positive correlations were found (all two tailed, all 
n=28) between scores at baseline assessment and first re-assessment (r = 0.984, 
p<0.01) and between baseline and second re-assessment (r = 0.939, p<0.01). In 
addition there was significant correlation between the first re-assessment and second 
re-assessment (r = 0.933, p<0.01).  
 
Provision of training 
 It was hypothesised that the provision of training on the participant’s 
medication would increase the ability of the participants to give informed consent to 
their medication. The mean total scores (and standard deviations) for each type of 
medication on each occasion of the A-ACQ measurement are shown in Table 2. The 
scores increased from baseline assessment to second re-assessment (post-intervention) 
for all of the three medication groups.  
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_______________________________________________ 
Table 2 about here 
_______________________________________________ 
 
 For the statistical analysis, Mauchly’s test indicated that the assumption of 
sphericity had been violated (chi-square = 12.53, p<0.01); therefore degrees of 
freedom were corrected using Greenhouse-Geisser estimates of sphericity (epsilon = 
0.71). The results indicated that the scores on the A-ACQ’s (baseline, first and second 
re-assessment) differed significantly, F(1.42, 35.55) = 180.60, p<0.01; partial eta 
squared =0.88, indicating a large effect .  The results indicated that there was no 
significant interaction effect between occasions (of assessment) and medication 
group: F (2.84, 35.55) = 4.21, p>0.01. The between subjects effects (medication 
group) was also not significant: F (2, 25)=0.054, p>0.01. 
 Post-hoc tests (Bonferroni) revealed that there was no significant difference 
between scores on the A-ACQ at baseline assessment and at first re-assessment 
(control) (P>0.01) when no training (intervention) had been administered. However, 
there was a highly significant difference between scores at baseline when compared to 
scores at second re-assessment (after the training had been implemented) (P<0.01). 
There was also a highly significant difference between scores at first re-assessment 
(control) and second re-assessment (post-training). This suggested that the provision 
of training (information) had increased the participants’ knowledge of their 
medications, as measured by the A-ACQ and subsequently, increased their capacity to 
give informed consent to taking medication.  
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The scores on the A-ACQ across the medication groups improved on all the 
questions after training, except for question six, where the scores remained unchanged 
(see Table 3).  
 
_______________________________________________ 
Table 3 about here 
_______________________________________________ 
Capacity to consent to medication 
 For a participant to be judged as having capacity to consent to their 
medication, they had to gain a score of at least one point on each of the questions on 
the A-ACQ. Overall, of the 28 participants, only two (7%) participants were judged 
able to consent to their medication at baseline and first re-assessment. This increased 
to six (21%) participants who were judged able to consent to their medications at the 
second re-assessment, after training, which fell just short of a significant increase 
(Fisher’s exact test p=0.04).  
Discussion 
This study investigated whether the provision of training (information) on 
medication would increase the capacity of people with mild to moderate intellectual 
disabilities to give informed consent to taking their medication. The 28 participants 
included in this study were taking either Epilim, Metformin or Haloperidol 
medications. Possible improvements in knowledge included: the function of 
medication, possible side-effects, risks, benefits and alternatives to medication. It was 
also hypothesised that individuals who had a higher level of receptive language 
comprehension would have gained higher scores on the A-ACQ. With respect to the 
research hypotheses, analysis using Pearson’s correlations showed highly significant 
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correlations were found between BPVS-II scores and scores on the A-ACQ at 
baseline (pre-training), first (control) and second re-assessment (post-treatment), 
indicating that those with better verbal comprehension were more likely to have 
capacity to consent to treatment, as others have also found (Arscott et al, 1999). 
Analysis on the A-ACQ scores using a two factor mixed factorial ANOVA indicated 
that there was no significant difference in the scores between medication groups on 
the A-ACQ, showing that groups did not differ on the A-ACQ before or after training 
was provided.  
 However, a highly significant difference was found on the A-ACQ between 
scores at baseline and those at second re-assessment. There was also a highly 
significant difference between scores at first re-assessment (control) on the A-ACQ 
and second re-assessment. This suggested that the provision of training (information) 
had increased the participants’ knowledge of their medications, as measured by the A-
ACQ and consequently, had increased their capacity to give informed consent to 
taking their medication. This increase in knowledge was weakly correlated with the 
participants’ verbal comprehension, suggesting that it may be that those with higher 
verbal comprehension may benefit more from training. 
An overall increase in scores on the A-ACQ was found after training had been 
provided across the three medication groups, except for in question 6 (whether they 
should carry on taking the tablets), which remained predominantly unchanged. It is 
difficult to know why this remained unchanged but it is possible that the wording of 
the question influenced participants, as it reminded them that their doctor had said 
they should take the tablets and there is a very clear power differential between the 
participants and their GP, so they may have been reluctant to contradict their GP’s 
opinion. 
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 A stringent criterion was employed to judge if a participant had capacity to 
consent to their medication before and after training was given. For an individual to 
be judged capacitous they had to score one point on each of the questions on the A-
ACQ. If a score of zero was given for any of the questions, the participant was not 
included as having capacity. Increases in capacity occurred in all three groups after 
the provision of training, an overall increase from 1 participant (4%) to 6 participants 
(21%). The precise criteria used are of course debatable but the scoring criteria and 
the judgment of capacity utilised in this study were similar to those used by Arscott et 
al. (1999), who also found a correlation between capacity to consent and verbal 
ability. Their study used the ACQ questionnaire and also a scoring system that 
allowed a participant to score 0, 1 or 2 on each question. For an individual to be 
judged as capacitous in their study, they had to gain at least one point on each of the 
questions on the ACQ. This scoring procedure was also adopted in this study as it was 
thought more sensitive than the one employed in the original three vignettes used by 
Morris et al. (1993), where a participant could only score zero or one on the 
assessment.  
 People with intellectual disabilities have a well-recognised raised risk of co-
morbid health problems (DoH, 2001)  and yet there is a lack of research on the safety 
of medication within this population. It is therefore important that alternatives to 
medication, for example, psychological treatment like anger management 
programmes, are offered as alternatives for the individual (Reiss & Aman, 1998), and 
it is particularly important for people to make their own decisions regarding taking   
medication. Recent audits of capacity and consent in those individuals with 
intellectual disabilities taking medication have indicated that this is a frequently 
neglected issue (Unwin & Shoumitro, 2008; Roy, Jain, Roy, Ward et al., 2011). 
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 The results of this study are encouraging in that, unlike Strydom and Hall’s 
study (2001), the provision of detailed information formatted in a way that individuals 
with intellectual disabilities can understand appeared to be a useful way to raise 
knowledge on medications. Individuals with intellectual disabilities, like anyone else, 
should be given information about the function of their medication, reasons for 
prescription, side-effects, risks and benefits and alternatives to taking the medication. 
Such information may need to be presented in substantial training sessions, as in this 
study, rather than simply by leaflets (as in Strydom & Hall, 2001). The training 
materials in this study were very accessible, the information was straightforward and 
clear, and participants were encouraged to ask questions and seek clarification. This is 
likely to be more effective than a leaflet. 
The participants in this study had been receiving their medication for many 
years. They may have simply continued from habit. What is important in the future is 
for medical and nursing staff to provide this kind of information and training before 
people begin taking medication, or at least shortly afterwards if the situation is 
considered urgent, so that people with intellectual disabilities get a realistic chance of 
making their own decisions. 
 In terms of the strengths of this study, it is important to note that it concerned 
assessing capacity in people with intellectual disabilities in a real situation (like in 
Wong et al, 2000), rather than simply assessing capacity using fictional vignettes (as 
in Morris et al, 1993; Arscott et al, 1999;  Cea & Fisher, 2003). Moreover it aimed to 
increase people’s capacity to consent to treatment, using training sessions, something 
several researchers have felt would be useful but has not been done as yet. There were 
some methodological limitations in the study however: the number of participants 
recruited was small and caution needs to be applied when generalising the results. 
                      Training to Give Informed Consent to Medication    
 19 
There was no formal control group used to compare the group that received training 
with a group of participants that did not receive this intervention. However, this was 
addressed by having a re-assessment of the participants after a short period of time to 
ensure there were no significant changes on the A-ACQ scores when no training had 
been provided. Another limitation is that there was no follow-up assessment to assess 
if the improvements in knowledge of medication were maintained after the training 
period had ceased. Moreover, the researchers rating the answers to questions were not 
blinded to the participant’s receipt of training, and only participants able to consent to 
the research were included, so we know very little about possible changes with 
training for those unable to consent to research. In terms of future studies, it would be 
useful to carry out the training package with a larger group of participants, 
randomising the participants to training and no-training groups, and keeping the raters 
blind to participants’ groups. This could be achieved by recruiting participants across 
multiple sites and including a wider range of medications.  
It would also be important to offer some training to carers, as it has been 
reported that carers seemed to lack knowledge about reasons why the disabled person 
in their care was prescribed medication and the relevant side effects. The majority of 
carers in several studies stated that they believed that they did not have adequate 
information (Christian et al, 1999; Heslop et al., 2005; Fretwell & Felce, 2007). 
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Table 1. Questions for each medication type 
Medication Questions 
Epilim 1. You have epilepsy. What effect can this have on you? 
2. You have epilepsy. Can you tell me what things your doctor has already tried to 
stop you from having a fit? 
3. Your doctor suggested a treatment to help to reduce the number of fits you have. 
What did he do to help to reduce the fits? 
4. The doctor gave you some tablets. Can you tell me some good things AND some 
bad things that could happen to you if you continue to take the 
tablets? 
5(a). The doctor gave you some tablets to reduce the number of fits. What can you 
do now?  
5(b). What do you think would happen if you said no to taking the tablets? 
6. The doctor has suggested you take the tablets. What do you think you should say 
about taking the tablets now? Why do you think you should say 
this? 
Metformin 1. You have diabetes, which means your blood sugar is high. What effect can this 
have on you? 
2. You have diabetes. Can you tell me what things your doctor has already tried to 
reduce your blood sugar? 
3. Your doctor has suggested a treatment to help to reduce your blood sugar levels. 
What did he do to help to reduce your blood sugar?  
4. The doctor gave you some tablets. Can you tell me some good things AND some 
bad things that could happen to you if you continue to take the 
tablets? 
5(a). The doctor gave you some tablets to reduce your blood sugar levels. What can 
you do now?  
5(b). What do you think would happen if you said no to taking the tablets? 
6. The doctor has suggested you take the tablets. What do you think you should say 
about taking the tablets now? Why do you think you should say 
this? 
Haloperidol 1. You sometimes feel angry. What has happened in the past when you get angry? 
2. You sometimes feel angry. Can you tell me what things your doctor has tried so 
far to help to control your anger? 
3. Your doctor suggested a treatment to help you control your anger. What did he do 
to help to reduce your anger? 
4. The doctor gave you some tablets. Can you tell me some good things AND some 
bad things that could happen to you if you continue to take the 
tablets? 
5(a). The doctor gave you some tablets to help to control your anger.     What can 
you do now?  
5(b). What do you think would happen if you said no to taking the tablets? 
6. The doctor has suggested you take the tablets. What do you think you should say 










Table 2. Mean scores and standard deviations on A-ACQ for each medication at each 
occasion 
 
    A-ACQ mean scores (and standard deviations) 




Epilepsy (n=16) 4.69 (1.99) 4.81 (1.94) 6.38 (2.19) 
Haloperidol (n=5) 4.20 (2.95) 4.40 (2.70) 6.60 (2.88) 














Table 3. Percentage of participants with various scores on the A-ACQ for all 























Question        
1 7.14 50 42.86  0 14.29 85.71 
2 17.86 60.71 21.43  0 42.86 57.14 
3 32.14 64.29 3.57  14.29 67.86 17.85 
4 42.86 57.14 0  32.14 60.71 7.15 
5a 60.71 39.29 0  35.71 60.71 3.58 
5b 60.71 39.29 0  53.57 46.43 0 
6 75 25 0  75 25 0 
 
 
 
 
